Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform

International Journal of Pharmaceutics

Volumn 460, Issue 1-2, 2014, Pages 131-143

  Choudhury, Hira ^a   Gorain, Bapi ^a   Karmakar, Sanmoy ^a   Biswas, Easha ^a   Dey, Goutam ^b   Barik, Rajib ^c   Mandal, Mahitosh ^b   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY   (India)

^c TCG Life Sciences Ltd   (India)

Author keywords

Breast cancer cell line; Caco 2 permeability; Nanoemulsion; Oral bioavailability; Paclitaxel; Stability

Indexed keywords

CAPROYL 90; DNA; OIL; PACLITAXEL; POLYSORBATE 20; TRIACETIN; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL STRAIN CACO 2; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIALYSIS; DISPERSION; DNA FRAGMENTATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG UPTAKE; IC 50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MONOLAYER CULTURE; MOUSE; NANOEMULSION; NONHUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; SHELF LIFE; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TANDEM MASS SPECTROMETRY; THERMODYNAMICS; TITRIMETRY; VISCOSITY; ZETA POTENTIAL;

BREAST CANCER CELL LINE; CACO-2 PERMEABILITY; NANOEMULSION; ORAL BIOAVAILABILITY; PACLITAXEL; STABILITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; EMULSIONS; HUMANS; MICE; NANOSTRUCTURES; PACLITAXEL; PERMEABILITY; SOLVENTS; SURFACE-ACTIVE AGENTS; VISCOSITY;

EID: 84888635702     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.10.055     Document Type: Article

References (48)

1. M. Agüerosa, L. Ruiz-Gatóna, C. Vauthierb, K. Bouchemalb, S. Espuelasa, G. Ponchelb, and J.M. Irachea Combined hydroxypropyl-β- cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel Eur. J. Pharm. Sci. 38 2009 405 413
2. V. Bali, M. Ali, and J. Ali Novel nanoemulsion for minimizing variations in bioavailability of ezetimibe J. Drug Target. 18 2010 506 519
3. V. Bali, M. Ali, and J. Ali Nanocarrier for the enhanced bioavailability of a cardiovascular agent: In vitro. pharmacodynamic, pharmacokinetic and stability assessment Int. J. Pharm. 403 2011 46 56
4. S. Bansal, and A. DeStefano Key elements of bioanalytical method validation for small molecule AAPS J. 9 2007 E109 E114
5. H.A. Bardelmeijer, M. Ouwehand, J.H. Beijnen, J.H. Schellensa, and O. Van Tellingen Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice Invest. New Drugs 22 2004 219 229 (Pubitemid 39012561)
6. H. Choudhury, B. Gorain, S. Karmakar, and T.K. Pal Development and validation of RP-HPLC method: scope of application in determination of oil solubility of paclitaxel J. Chromatogr. Sci. 2013 10.1093/chromsci/bms206
7. P.P. Constantinides Lipid microemulsions for improving drug dissolution and oral absorption and biopharmaceutical aspects Pharm. Res. 12 1995 1561 1572 (Pubitemid 26005509)
8. S. Das, K.K. Dey, G. Dey, I. Pal, A. Majumder, S. MaitiChoudhury, S.C. Kundu, and M. Mandal Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma PLoS ONE 7 2012 10.1371/journal.pone.0046641
9. H. Eroglu, B.B. Nihan, U. Serdar, and O. Levent Preparation and in vitro/in vivo evaluation of microparticle formulations containing meloxicam AAPS PharmSciTech 13 2012 46 52
10. Food and Drug Administration of the United States Guidance for Industry Bioanalytical Method Validation May 2001 http://www.fda.gov/cder/guidance/index. html (accessed: 12.11.11)
11. S. Ganta, H. Devalapally, and M. Amiji Curcumin enhances oral bioavailability and antitumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation J. Pharm. Sci. 99 2010 4630 4641
12. K. Gao, J. Sun, K. Liu, X. Liu, and Z. He Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel Drug Dev. Ind. Pharm. 34 2008 1227 1237
13. F. Gao, Z. Zhang, H. Bu, Y. Huang, Z. Gao, and J. Shen Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism J. Control. Release 149 2011 168 174
14. Y. Gavrieli, Y. Sherman, and S.A. Bensasson Identification of programmed cell-death in situ via specific labeling of nuclear-DNA fragmentation J. Cell Biol. 119 1992 493 501
15. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598 (Pubitemid 32778603)
16. J.J. Grau, M. Caballero, E. Verger, M. Monzo, and J.L. Blanch Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients Acta Otolaryngol. 129 2009 1294 1309
17. H. Green, P. Soderkvist, P. Rosenberg, R.A. Mirghani, P. Rymark, E.A. Lundqvist, and C. Peterson Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer Basic Clin. Pharmacol. Toxicol. 104 2009 130 137
18. S.K. Jaganathan, A. Mazumdar, D. Mondhe, and M. Mandal Apoptotic effect of eugenol in human colon cancer cell lines Cell Biol. Int. 35 2011 607 615
19. S. Kakumanu, J.B. Tagne, T.A. Wilson, and R.J. Nicolosi A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension Nanomedicine 7 2011 277 283
20. S. Khandavilli, and R. Panchagnula Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats J. Invest. Dermatol. 127 2007 154 162 (Pubitemid 46005673)
21. P.E. Kintzel Prophylaxis for paclitaxel hypersensitivity reactions Ann. Pharmacother. 35 2001 1114 1117 (Pubitemid 32880032)
22. X. Li, N. Anton, T.M.C. Ta, M. Zhao, N. Messaddeq, and T.F. Vandamme Microencapsulation of nanoemulsions: novel trojan particles for bioactive lipid molecule delivery Int. J. Nanomed. 6 2011 1313 1325
23. C. Lovelyn, and A.A. Attama Current state of nanoemulsions in drug delivery J. Biomater. Nanobiotechnol. 2 2011 626 639
24. A.N. Martin Martin's Physical Pharmacy and Pharmaceutical Sciences sixth edition 2011 Lippincott Williams & Wilkins Publishers Philadelphia 419 429
25. N.I. Marupudi, J.E. Han, K.W. Li, V.M. Renard, B.M. Tyler, and H. Brem Paclitaxel: a review of adverse toxicities and novel delivery strategies Expert Opin. Drug Saf. 6 2007 609 621 (Pubitemid 351308218)
26. R.L. Oostendorp, T. Buckle, G. Lambert, J.S. Garrigue, J.H. Beijnen, J.H.M. Schellens, and O. van Tellingen Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice Invest. New Drugs 29 2011 768 776
27. B. Overmoyer Options for the treatment of patients with taxane-refractory metastatic breast cancer Clin. Breast Cancer 8 2008 S61 S70
28. S. Peltier, J.M. Oger, F. Lagarce, W. Couet, and J.P. Benoit Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules Pharm. Res. 23 2006 1243 1250 (Pubitemid 43946146)
29. S. Poullain-Termeau, S. Crauste-Manciet, D. Brossard, S. Muhamed, G. Nicolaos, R. Farinotti, C. Barthelemy, H. Robert, and P. Odou Effect of oil-in-water submicron emulsion surface charge on oral absorption of a poorly water-soluble drug in rat Drug Deliv. 15 2008 503 514
30. H. Ragelle, S. Crauste-Manciet, J. Seguin, D. Brossard, D. Scherman, P. Arnaud, and G.G. Chabot Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice Int. J. Pharm. 427 2012 452 459
31. E.K. Rowinsky, E.A. Eisenhauer, V. Chaudhry, S.G. Arbuck, and R.C. Donehower Clinical toxicities encountered with paclitaxel (TAXOL) Semin. Oncol. 20 1993 1 15 (Pubitemid 23239390)
32. E.K. Rowinsky, and R.C. Donehower Paclitaxel (taxol) N. Engl. J. Med. 332 1995 1004 1014
33. M.M. Schittenhelm, C. Kollmannsberger, K. Oechsle, A. Harlow, J. Morich, F. Honecker, R. Kurek, S. Storkel, L. Kanz, C.L. Corless, K.K. Wong, C. Bokemeyer, and M.C. Heinrich Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer Mol. Cancer Ther. 8 2009 481 489
34. S. Shafiq, F. Shakeel, S. Talegaonkar, F.J. Ahmad, R.K. Khar, and M. Ali Development and bioavailability assessment of ramipril nanoemulsion formulation Eur. J. Pharm. Biopharm. 66 2007 227 243 (Pubitemid 46667230)
35. R.E. Smith, A.M. Brown, E.P. Mamounas, S.J. Anderson, B.C. Lembersky, J.H. Atkins, H.R. Shibata, L. Baez, P.A. DeFusco, E. Davila, S.J. Tipping, J.D. Bearden, and M.P. Thirlwell Randomized trial of 3-hour versus 24-hour infusion of high dose paclitaxel in patients with metastatic or locally advanced breast cancer. National Surgical Adjuvat Breast and Bowel Protocol B-26 J. Clin. Oncol. 17 1999 3403 3411 (Pubitemid 29517907)
36. A. Sparreboom, L. van Zuylen, E. Brouwer, W.J. Loos, P. de Bruijn, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications Cancer Res. 59 1999 1454 1457 (Pubitemid 29160110)
37. H. Sun, K. Liu, W. Liu, W. Wang, C. Guo, B. Tang, J. Gu, J. Zhang, H. Li, X. Mao, Q. Zou, and H. Zeng Development and characterization of a novel nanoemulsion drug-delivery system for potential application in oral delivery of protein drugs Int. J. Nanomed. 7 2012 5529 5543
38. S.B. Tiwari, and M.M. Amiji Improved oral delivery of paclitaxel following administration of nanoemulsion formulations J. Nanosci. Nanotechnol. 6 2006 1 7
39. A.E. vanHerwaarden, E. Wagenaar, C.M. van der Kruijssen, R.A. van Waterschoot, J.W. Smit, J.Y. Song, M.A. van der Valk, O. van Tellingen, J.W. van der Hoorn, H. Rosing, J.H. Beijnen, and A.H. Schinkel Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism J. Clin. Invest. 117 2007 3583 3592 (Pubitemid 350097013)
40. O. van Tellingen, M.T. Huizing, V.R. Panday, J.H. Schellens, W.J. Nooijen, and J.H. Beijnen Cremophor EL causes (pseudo-) nonlinear pharmacokinetics of paclitaxel in patients Br. J. Cancer 81 1999 330 335 (Pubitemid 29423714)
41. S.A. Veltkamp, B. Thijssen, J.S. Garrigue, G. Lambert, F. Lallemand, F. Binlich, A.D.R. Huitema, B. Nuijen, A. Nol, J.H. Beijnen, and J.H.M. Schellens A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer Br. J. Cancer 95 2006 729 734 (Pubitemid 44373489)
42. P. Venkatesan, N. Puvvada, R. Dash, B.N.P. Kumar, D. Sarkar, B. Azab, A. Pathak, S.C. Kundu, P.B. Fisher, and M. Mandal The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer Biomaterials 32 2011 3794 3806
43. D.A. Volpe, E.B. Asafu-Adjaye, C.D. Ellison, S. Doddapaneni, R.S. Uppoor, and M.A. Khan Effect of ethanol on opioid drug permeability through Caco-2 cell monolayers AAPS J. 10 2008 360 362
44. S.P. Vyas, and R.K. Khar Submicroemulsions S.P. Vyas, R.K. Khar, Targeted and Controlled Drug Delivery: Novel Carrier Systems 2004 CBS Publishers New Delhi 280 302
45. R.B. Weiss, R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.J. Gralla, D.L. Trump, J.R. Baker Jr., D.A. Van Echo, D.D. Von Hoff, and B. Leyland-Jones Hypersensitivity reactions from taxol J. Clin. Oncol. 8 1990 1263 1268 (Pubitemid 20195638)
46. Y. Wang, K.C. Wu, B.X. Zhao, X. Zhao, X. Wang, S. Chen, S.F. Nie, W.S. Pan, X. Zhang, and Q. Zhang A novel paclitaxel microemulsion containing a reduced amount of cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety J. Biomed. Biotechnol. 2011 10.1155/2011/854872
47. S. Yang, R.N. Gursoy, G. Lambert, and S. Benita Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors Pharm. Res. 21 2004 261 270 (Pubitemid 38221971)
48. C. Zhang, G. Qu, Y. Sun, X. Wu, Z. Yao, Q. Guo, Q. Ding, S. Yuan, Z. Shen, Q. Ping, and H. Zhou Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel Biomaterials 29 2008 1233 1241